Upon joining the study, you will be randomly assigned to one of two groups: the **intermittent maximum androgen blockade (iMAB)** group or the **continuous maximum androgen blockade (cMAB)** group.

This assignment will determine the course of your treatment during the trial.

If you are in the **iMAB** group, your treatment will be paused after achieving a deep response, defined as a **PSA level** of 0.2 ng/mL or lower, for a period of up to one year.

If you are in the **cMAB** group, you will continue receiving treatment without interruption.

The medications used in this trial may include **darolutamide**, **goserelin acetate**, **leuprorelin acetate**, **apalutamide**, **relugolix**, **enzalutamide**, **abiraterone**, and **triptorelin acetate**. These medications are administered either orally or through injections.

Throughout the trial, regular assessments will be conducted to monitor your health and the effectiveness of the treatment.

These assessments will include measuring your **PSA levels**, checking your testosterone levels, and evaluating your overall health and quality of life.

You will be asked to complete questionnaires about your physical functioning, sexual activity, pain, and fatigue.

At the end of the treatment phase, a comprehensive evaluation will be conducted to assess the outcomes of the trial.

This evaluation will include a review of your **PSA levels**, testosterone levels, and overall survival.

The results will help determine the effectiveness and safety of the intermittent treatment approach compared to continuous treatment.

After the treatment phase, follow-up assessments will continue for up to three years to monitor long-term effects and outcomes.

These follow-ups will include regular health check-ups and assessments of your quality of life.

The information gathered during this period will contribute to understanding the long-term benefits and risks of the treatment strategies.